Is Risk in your DNA?I hope to get perspective from others looking at this company. Is this whole sector with pharmacy overlooked? CVS poses as a play in brand? I am no marketing expert.
Biotech
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation.
The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges.
Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
Wave Life Sciences (WVE) AnalysisCompany Overview:
Wave Life Sciences NASDAQ:WVE is a pioneer in RNA-targeted therapies, focusing on rare genetic diseases and conditions with significant unmet medical needs.
Key Growth Catalysts:
Breakthrough in RNA Editing 🧬
WVE-006: Demonstrates the first-ever in-human evidence of RNA editing, a historic milestone for RNA medicine.
This platform unlocks new opportunities to treat genetic diseases with precision, differentiating Wave from peers.
Expanding Obesity Market Opportunity 🌟
WVE-007: A promising GalNAc-siRNA therapy targeting INHBE, addressing the multi-billion-dollar obesity market.
Clinical trials begin in Q1 2025, offering a potential blockbuster treatment for obesity—a market in high demand.
Duchenne Muscular Dystrophy (DMD) 🚀
WVE-N531: Positive interim data highlights its potential to secure accelerated approval, providing new hope for DMD patients.
Innovative Pipeline & Chemistry 🔬
Wave’s PRISM platform and advanced stereopure chemistry give it a competitive edge in RNA therapeutics.
A robust pipeline targeting various high-value indications reinforces long-term growth prospects.
Investment Outlook:
Bullish Stance: We are bullish on WVE above $12.50-$13.00, driven by groundbreaking RNA editing advancements, an expanding obesity opportunity, and promising DMD data.
Upside Target: Our price target is $24.00-$25.00, reflecting transformative potential across multiple programs and significant upside in addressing major unmet medical needs.
🔹 Wave Life Sciences—Unlocking the Power of RNA Medicine! #WVE #RNAEditing #Biotech #Innovation
$CRSP: A BioTech to add to the watchlist! 95% UpsideNASDAQ:CRSP
Not a High Five Setup...yet
-H5 Indicator is GREEN
-Filling Volume Profile GAP and setting up at a new Volume Profile Shelf
-Need Wr% to push up above -20 and form Williams Consolidation Box
-Need to breakout of Symmetrical Triangle at $56ish
If we get that it will be a H5 Trade and look for targets:
🎯$73 🎯$91 📏$110 ⏳Before mid-2026
NFA
CAPR projected to see additional volatility NEAR TERM. Recent short attack will likely be a two-part process.
Expecting strong buy wave to 17-18.5 zone near term before renewed aggressive selling down to next liquidity target zone at 10.4-11 level.
There exists a small gap at 9.95-10.05 which may be targeted by shorts. Unsure if it gets filled during market hrs or during extended session.
Planning to go long again from 10.4-11 via limit buy orders sometime this month. Expecting us to get the buy opportunity before 12/20 date before the next swing target to 25.00
once we see a break above 26.5, it'll confirm for me the greater buy sequence will continue on weekly timeframe for advancement to 75-80$ analyst target level. Until then, we may remain rangebound between 15-25$ levels.
Personally expecting price to reach 100$ sometime by late 2025.
This BioTech is about to EXPLODE! 165%+ Move InboundChart #4/ 40: NASDAQ:ALGS ⚕️
-Falling Wedge Breakout
-H5 Indicator is Green
-Volume Shelf Launch
-Williams Consolidation Box Thriving
🎯 $60📏 $68 ⏳ Before 2027
NFA
Healthcare Sector Poised For A 7% to 15% Rally Into Early 2025My continued research to help traders shows the US Healthcare and Biotech sectors are poised for a very large rally phase into early 2025.
Particularly, XLV and XBI seem uniquely setup to rally more than 9-10% over the next 60 to 90+ days.
This video explains how I use my Adaptive Dynamic Learning Predictive Modeling system to find opportunities other people miss.
Using technology, predictive modeling, and inference engines like this is one advantage I have because I can build any type of technology or system I like - and use it on any symbol or interval I like.
Now is the time to prepare for the big moves headed into 2025. Follow my research if you want to target the biggest price swings in the markets.
Get some.
#trading #research #investing #tradingalgos #tradingsignals #cycles #fibonacci #elliotwave #modelingsystems #stocks #bitcoin #btcusd #cryptos #spy #es #nq #gold
ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30.
A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years...
Target #1 = $1.75
Target #2 = $2.50
Target #3 = $2.95
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀
Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed.
With more probabilities on our side, the likelihood of success is through the roof! 📈💥
Check it out, and let’s ride this wave together! 🌊
Stay tuned for more insights! 🔔
NFA
#Trading #StockMarket #Biotech #Investing #HighFiveSetup
A 14% drop in $VKTX and I might still win. Here's why! NASDAQ:VKTX
A 14% drop in NASDAQ:VKTX and I might still win. Here's why!
In this video analysis update on my position in NASDAQ:VKTX , we will discuss why I didn't sell after the 14% pullback and why it's important not to sell based on price movement! Enjoy.
Have you ever sold a stock and right after it flew to the upside?
Prescription for Gains!Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49.
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
NASDAQ:RXRX
Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio but also opens up new revenue channels for the company.
Key Developments:
Strong Revenue Generation: Argenx demonstrates a robust global presence with revenue streams across various regions:
U.S.: $407 million
Japan: $20 million
EMEA: $35 million
China: $14 million
This diversified revenue generation helps mitigate regional risks and showcases the company’s ability to penetrate multiple markets effectively.
Upcoming Trials: The company plans to launch four new registration trials by the end of 2024, further expanding its therapeutic offerings. This proactive approach to research and development positions Argenx for future growth and diversification in its product line.
Strategic Collaboration: Argenx's collaboration with Monarch is aimed at enhancing operational efficiency and customer service. This partnership is expected to boost market penetration and strengthen the company's competitive edge.
Investment Outlook: Bullish Outlook: We are bullish on ARGX above the $484.00-$489.00 range, driven by its recent FDA approval, diverse revenue streams, and plans for further clinical expansion. Upside Potential: Our target for Argenx is set at $740.00-$750.00, supported by the company’s strong market presence and growth initiatives.
🚀 ARGX—Pioneering the Future of Autoimmune Treatments. #Biotech #AutoimmuneTherapy #MarketGrowth
RXRX - BIOTECH SQUEEZE PLAY RXRX - Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines.
Consolidating since April, look left and see the explosive moves.
Grab cheap long dated calls and wait for news to come out. Easy R/R. Calls swing 100% on small moves and I've got a good bit cheaply Jan 2025 calls. 9 & 10 dollar strikes.
Huge opportunity here to cash in on any news or favorable Earnings Report in a few days.
Short squeeze targets 10-12 dollars, manage your own risk. Will be dumping calls on impulsive move.
$6 looks to be a strong bottom here, under that for any time other than a flash sale, this trade is invalid, and I won't be holding any calls.
NOT INVESTMENT ADVICE. TRADE YOUR PLAN!
Thanksgiving Gifts for ALL - RXRX - BIOTECH SQUEEZE PLAYRecursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives.
Chart looks primed, bounced off 6 dollar range a few times and is peaking out of the downtrend. I fully expect to find support along that trendline and chop until news sends this thing flying.
Short squeeze potential here and fibs look like a big move could be in store before Thanksgiving which will line up with news around Earnings time.
Holding long dated calls and some shares.
Calls dated Jan 2025 or later. 8,9,10 strikes
Fibs for targets.
LFG!
ROSSARI BIOTECHRossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India
Their 3 main product categories are:
- Home, personal care, and performance chemicals
- Textile specialty chemical
- Animal health and nutrition
The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT Bombay.
Protagonist Therapeutics (PTGX) AnalysisMarket Position and Growth Drivers:
Protagonist Therapeutics NASDAQ:PTGX is poised for substantial growth, with its recent inclusion in the S&P Small Cap 600 likely attracting significant institutional buying and boosting its stock price.
Strategic Partnership:
The company's partnership with Takeda to develop and market Rusfertide has already resulted in a $300 million upfront payment. Promising Phase II trial results for Rusfertide could lead to substantial profits through opt-out payments, milestone payments, and royalties.
Investment Outlook:
Bullish Outlook: We are bullish on PTGX above the $31.50-$32.00 range.
Upside Potential: With an upside target set at $48.00-$50.00, investors should consider Protagonist Therapeutics' strategic partnership and promising clinical results as key drivers for future stock appreciation.
📊🔬 Monitor Protagonist Therapeutics for promising investment opportunities! #PTGX #Biotech 📈🔍
XBI - wyckoff phase D to ESelf explanatory, we are in phase D about to enter Phase E. LEAP option strategy might be a good one.
Twist Biosciences (TWST) AnalysisInnovation and Market Leadership:
Twist Biosciences NASDAQ:TWST , a leader in synthetic DNA products, is set for substantial growth with its new Express Genes service, offering NGS-verified genes in just five to seven business days. This innovation is expected to strengthen Twist's market position and dominance.
Growth Forecast and Market Expansion:
The company forecasts a CAGR of over 28% through 2025, backed by a customer base of over 3,300 across various industries. Targeting multiple large addressable markets, Twist aims to sustain revenue growth for the foreseeable future.
Investment Outlook:
Bullish Outlook: We are bullish on TWST above the $41.00-$42.00 range.
Upside Potential: With an upside target set at $76.00-$78.00, investors should consider Twist's innovative service offerings and robust growth projections as key drivers for potential stock appreciation.
📊🧬 Monitor Twist Biosciences for promising investment opportunities! #TWST #SyntheticDNA 📈🔍
SIGA Technologies Analysis 6/24Disclosure: As of 6/24 I am long SIGA Technologies NASDAQ:SIGA
SIGA Technologies is a bio pharmaceuticals company that is in the public health market. They develop and sell products to treat Smallpox, Ebola, and other public health threats.
Management Effectiveness: The company has been consistently profitable since 2018, with margins averaging 30%-40% in recent years with only a few unprofitable quarters.
Very quickly after the company became profitable they brought the debt to essentially nothing.
In recent years the company's return on equity has been above 25%, indicating their research spending is used effectively.
The company has a large cash position for potential investment in research.
Valuation The company trade at a P/E of 6 and a p/cf of 8 they have paid special dividends for several years and could potentially implement a stock buyback program, at least that is something I would be considering if I were a board member (Disclosure: I am not a board member obviously).
Summary NASDAQ:SIGA is a well run company, trading at an excellent valuation if you are willing to take the risk of a concentrated portfolio of products and volatile returns. They have several positive tailwinds including: International Expansion, Re-Valuation of the company due to implementation of a dividend or buyback policy, and increased public health awareness by international governments.
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position.
Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case.
Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above.
Here on my macroeconomic and current research shortlist watchlists:
www.tradingview.com
www.tradingview.com
Thanks for reading, have a good one
Nurix Therapeutics (NRIX) Analysis Clinical Milestone:
Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win."
Strategic Collaborations:
Nurix is also advancing collaborations with major pharma companies. It is set to nominate a development candidate with Sanofi this year, positioning it for substantial breakthroughs. Additionally, Gilead Sciences extended its research collaboration with Nurix by two years, highlighting Nurix's robust R&D capabilities.
Investment Outlook:
Bullish Outlook: We are bullish on NRIX above the $15.00-$16.00 range.
Upside Potential: With a target set at $30.00-$31.00, investors should consider Nurix's promising clinical results and strategic partnerships as key drivers for potential stock growth.
📊🧬 Monitor Nurix Therapeutics for promising investment opportunities! #NRIX #Biotech 📈💊
XBI biotech ETF EW count optionsSharing an intermediate view of the EW count options for XBI.
The short-term bullish range is $97-$98.
The short-term bearish target ranges are $89 - $88.50 and $87.
The bearish count, in red, drops the price to $81ish as first support. If, $81 range does not hold, $72 is the C wave target.
In the meantime, I anticipate a lot of chop in the range from $86 - $100 in the next couple months until a rate cut occurs.
As speculation of a rate cut increases, the price can begin to gravitate toward $104. When an interest rate cut is proposed, XBI will blast to the $140s but I am reserved about this outcome at this time.
Dark Pools Accumulating Biotech: STOKDark Pools are accumulating some biotechnology stocks for mutual funds and ETFs based on this new technology. HFTs are chasing this accumulation.
NASDAQ:STOK is now near the price when more professional traders are likely to swing trade. It has a very high Percentage of Shares Held by Institutions and the bottom is completed. It may be a potential candidate for a watchlist for this industry, IF the industry fits your needs for short-term trading or long-term investing. It may also turn into a position trade if platforms develop.
This is a Weekly Chart so all the history of recent price is visible. The peaks of bounces upward within the downtrend are where the stock may stall and go sideways as it moves up.
